Shares of UCB tumbled following a prominent analyst revision. The stock fell 3.6% to trade at EUR 265.1 after Barclays moved the company from Overweight to Equalweight and cut its price target to EUR 300 from EUR 310, citing a materially weaker earnings growth trajectory.
Barclays reduced its projected compound annual growth rate for EPS in fiscal years 2026 through 2029 from 24.4% to 21.5%. The bank also trimmed its EBITDA forecasts by low-to-mid single digits, a change that it said narrows the justification for the stock's prior premium valuation.
While Barclays nudged its sales forecasts for FY27, FY28 and FY29 marginally higher to account for stronger-than-expected performance from Bimzelx, UCB's core immunology treatment, the firm also credited three early-to-mid-stage bolt-on acquisitions completed in the first half of 2026. Even so, the overall tone of the update emphasized caution rather than optimism.
Barclays explicitly flagged meaningful downside risk to the equity, echoing concerns raised by other market watchers. Those earlier worries highlighted slowing prescription growth for Bimzelx in the U.S. and the potential for pricing pressure linked to Medicaid exposure and evolving drug-pricing policy headwinds.
The broader market did not add downward pressure to the stock on the day. Major U.S. indices were firmer, with the S&P 500 up 0.5% and the Dow Jones advancing 0.7%, indicating the move was largely company-specific rather than part of a wider market selloff. There were no major central bank decisions or economic releases noted as altering sentiment for European pharmaceuticals on the session.
Taken together, Barclays' decision appears to have crystallized previously circulating doubts about the sustainability of UCB's earnings growth at a time when the share price had been trading near the upper bound of its 52-week range of EUR 153.65 to EUR 289.50. With the next quarterly report not expected until late July, investors seem to be reassessing the interim risk-reward profile, which pushed the stock toward an intraday low of EUR 263.2.
What happened
- UCB shares declined 3.6% to EUR 265.1 after a Barclays downgrade and price-target cut.
- Barclays lowered its FY26-29 EPS CAGR forecast from 24.4% to 21.5% and trimmed EBITDA projections slightly.
- The firm increased FY27-29 sales estimates modestly to reflect Bimzelx strength and three small acquisitions completed in H1 2026.